Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. on August 30, 2018. The company is incorporated in Delaware and is designated as an emerging growth company. The report details corporate governance changes effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and associated compensation arrangements.
Material Changes
On August 30, 2018, the Board of Directors increased its size from eight to nine members. Meryl Zausner was elected as a Class II director and appointed to the Audit Committee.
Compensation and Governance Details
- Annual Retainer: $35,000 for board service.
- Audit Committee Retainer: $7,500 annually.
- Equity Award: Initial option to purchase 30,000 shares of common stock.
- Exercise Price: $8.47 per share (closing price on the grant date).
- Vesting Schedule: Equal installments over four years, contingent on continued service.
Investor Verification Checklist
- Confirm the total number of board seats and the composition of the Audit Committee.
- Verify the impact of the new equity grant on total share count and potential dilution.
- Review the company's standard director indemnification agreement for liability terms.
- Check subsequent filings for any changes to the vesting schedule or director tenure.